KW-6356: what does this study show?
168 patients in a randomized, double-blind trial: oral KW-6356 3 mg or 6 mg once daily versus placebo for 12 weeks.
The primary motor-examination score improved by 5.37 points with 3 mg, 4.76 with 6 mg and 3.14 with placebo. Constipation occurred in 7.3% and 10.3% of the active-dose groups.
This is disease-specific motor-function research, not a healthy-person focus or motivation trial. The abstract does not demonstrate disease modification.
These findings apply to the population and methods described above.
What might this mean, and what would change the interpretation?
This is disease-specific motor-function research, not a healthy-person focus or motivation trial. The abstract does not demonstrate disease modification.
What would clarify this: Independent replication with clinically meaningful outcomes and longer safety follow-up.
Findings reviewed · abstract
Checked Sep 23, 2026 against the linked abstract. This reading note is not a formal risk-of-bias appraisal.